- Conditions
- Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- radiation therapy, therapeutic conventional surgery, etoposide, ifosfamide, doxorubicin hydrochloride, cyclophosphamide, vincristine sulfate, topotecan hydrochloride, filgrastim
- Other · Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Monrovia, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 654
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
- Interventions
- filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
- Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, dexamethasone, etoposide, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 17 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Small Cell Lung Cancer Recurrent
- Interventions
- Debio 0123, Etoposide, Carboplatin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2011
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, pegfilgrastim, rituximab, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 1 Year
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, carmustine, cytarabine, etoposide, melphalan, methotrexate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Small Cell Lung Cancer
- Interventions
- M3814, Cisplatin, Etoposide
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 16
- States / cities
- Mesa, Arizona • Santa Rosa, California • Whittier, California + 12 more
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Melphalan, Mycophenolate Mofetil, Tacrolimus, Thiotepa
- Procedure · Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myeloid Leukemias, AML, Leukemia, CML
- Interventions
- Rapamycin, Mitoxantrone, Etoposide, Cytarabine, Rapamycin + MEC
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, cisplatin, cyclophosphamide, etoposide, methotrexate, vincristine sulfate, adjuvant therapy, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 10 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Danville, Pennsylvania
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
- Interventions
- Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 22 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2007
- U.S. locations
- 30
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 24 more
- Conditions
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- Yttrium Y 90 Basiliximab, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
- Interventions
- Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Diffuse Large B-Cell Lymphoma Unclassifiable
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Ibrutinib, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
- Interventions
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, Cyclophosphamide, Etoposide, Carboplatin, Dactinomycin, Vincristine Sulfate, Radiation Therapy, Laboratory Biomarker Analysis
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 161
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more
- Conditions
- Leukemia
- Interventions
- ara-C, Daunorubicin, Etoposide, PSC-833, Aldesleukin
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2010
- U.S. locations
- 33
- States / cities
- La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Daphne, Alabama • Hot Springs, Arkansas • Fort Myers, Florida + 17 more
- Conditions
- Lymphoma
- Interventions
- Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa, Carmustine, Cisplatin (CDDP), Cyclophosphamide, Cytarabine (ARA-C), Etoposide (VP-16), Idarubicin, Ifosfamide, Leucovorin Calcium, Melphalan, Methotrexate, Methylprednisolone, mitoxantrone hydrochloride (DHAD), Vincristine Sulfate, Peripheral Blood Stem Cell Transplantation, Radiation Therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neutropenia, Sarcoma
- Interventions
- filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 43
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 35 more
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 49 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more